OPR8 Antibody

What is ORP8 and why is it significant for antibody-based research?

ORP8 belongs to the oxysterol-binding protein (OSBP)-related protein family and functions as an endoplasmic reticulum membrane protein implicated in lipid trafficking. Research significance stems from its role in lipid transport between cellular membranes, particularly at endoplasmic reticulum-plasma membrane (ER-PM) contact sites. Antibodies against ORP8 are valuable tools for investigating membrane contact sites, phosphoinositide sensing, and lipid transfer mechanisms in cellular homeostasis. When designing antibody-based experiments, researchers should account for the existence of two naturally occurring ORP8 variants: the long form (ORP8L) and short form (ORP8S), which differ by a 42 amino acid stretch at the amino-terminal region . This structural difference influences cellular localization patterns and potentially antibody recognition sites, requiring careful epitope selection during antibody development and validation.

How do I distinguish between ORP8 isoforms using antibodies?

To distinguish between ORP8L and ORP8S isoforms, implement a multi-method approach combining immunoblotting with immunofluorescence microscopy. Use antibodies targeting the unique 42 amino acid region present only in ORP8L for selective detection of this isoform. For differential visualization, employ dual-labeling techniques with isoform-specific antibodies conjugated to distinct fluorophores. Western blot analysis should reveal different molecular weights: approximately 101 kDa for ORP8L and 97 kDa for ORP8S. When performing immunocytochemistry, note that both isoforms demonstrate distinct subcellular localization patterns - ORP8L typically shows reticular ER distribution while ORP8S may show more varied patterns . Validation controls should include overexpression systems using mCherry-tagged ORP8L and ORP8S constructs to confirm antibody specificity and cross-reactivity profiles.

What controls should be included when validating ORP8 antibodies?

A comprehensive ORP8 antibody validation protocol requires multiple controls to ensure specificity and reliability. Essential negative controls include:

• ORP8 knockdown/knockout cells or tissues using siRNA or CRISPR-Cas9 approaches

• Pre-adsorption of antibody with purified recombinant ORP8 antigen

• Secondary antibody-only controls to assess non-specific binding

Positive controls should incorporate:

• Cells overexpressing tagged ORP8 variants (such as mCherry-ORP8L or mCherry-ORP8S)

• Tissue samples with documented ORP8 expression

• Parallel validation with multiple antibodies targeting different ORP8 epitopes

For cross-reactivity assessment, evaluate antibody reactivity against the closely related ORP5 protein, which shares functional domains with ORP8. Additionally, include immunoprecipitation followed by mass spectrometry to confirm antibody specificity. Document antibody performance across multiple experimental conditions (fixation methods, blocking reagents, incubation times) to establish optimal working parameters for reproducible results.

How can I optimize immunofluorescence protocols for detecting endogenous ORP8?

Optimizing immunofluorescence for endogenous ORP8 detection requires careful consideration of fixation, permeabilization, and antigen retrieval methods due to ORP8's membrane association. For effective detection, implement a paraformaldehyde (4%) fixation followed by gentle permeabilization using digitonin (0.01-0.05%) rather than Triton X-100 to preserve membrane integrity. Include a blocking step with 5% BSA supplemented with 0.1% saponin to maintain accessibility to membrane-associated epitopes. When designing experiments, co-stain with established markers of the ER (calnexin or PDI) and ER-PM junctions (MAPPER) to confirm proper localization. For optimal signal-to-noise ratio, use tyramide signal amplification systems with overnight primary antibody incubation at 4°C. Critically, endogenous ORP8 detection can be challenging due to potential low expression levels; therefore, compare staining patterns with reported localizations showing reticular distribution for both ORP8L and ORP8S, with ORP8L demonstrating particular enrichment in the reticular ER .

What are the methodological considerations when using antibodies to investigate ORP8 in ER-PM contact sites?

Investigating ORP8 at ER-PM contact sites presents unique challenges due to these structures' small size and dynamic nature. Implement super-resolution microscopy techniques (STORM, PALM, or STED) combined with ORP8 antibodies to achieve nanoscale resolution of these junctions. For optimal visualization, perform dual immunolabeling with antibodies against ORP8 and established ER-PM contact site markers like MAPPER or STIM1 .

For ultrastructural analysis, implement one of two complementary electron microscopy approaches demonstrated effective for ORP8 localization:

• Immunogold labeling of GFP-ORP8 using anti-GFP antibodies for frozen section EM

• APEX2-based proximity labeling with GFP-binding protein-APEX2 constructs that generate electron-dense reaction products at ORP8-enriched sites

When analyzing PtdIns(4,5)P2-dependent recruitment of ORP8 to ER-PM junctions, employ co-expression systems with phosphatidylinositol-4-phosphate 5-kinase type-1 beta (PIP5K1b) to selectively increase PtdIns(4,5)P2 levels at the plasma membrane . Compare wild-type ORP8 localization to the R158Q mutant, which fails to translocate to ER-PM junctions despite elevated PtdIns(4,5)P2 levels, confirming the specificity of the observed recruitment.

How can ORP8 antibodies be used to study the regulation of phosphoinositide homeostasis?

To investigate ORP8's role in phosphoinositide homeostasis, implement antibody-based quantitative approaches combined with genetic manipulations. Design experiments that combine ORP8 immunoprecipitation with subsequent activity assays to measure lipid transfer capabilities. When investigating ORP8's impact on plasma membrane phosphoinositide levels, use a knockdown-rescue experimental design where endogenous ORP8 is depleted and replaced with structurally modified variants that can be differentially targeted by antibodies.

Research has shown that knocking down both ORP5 and ORP8 increases plasma membrane levels of PtdIns(4,5)P2 with minimal effect on PtdIns(4)P levels , suggesting these proteins function in phosphoinositide transport. To quantify these changes:

• Generate ORP8-depleted cell lines using siRNA or CRISPR-Cas9

• Quantify phosphoinositide levels using antibody-based biosensors or mass spectrometry

• Rescue with wild-type or mutant ORP8 constructs

• Validate protein expression using validated ORP8 antibodies

For temporal analysis of phosphoinositide dynamics, combine ORP8 immunostaining with live-cell imaging of phosphoinositide biosensors, allowing correlation between ORP8 localization changes and phosphoinositide redistribution in response to cellular stimuli.

What are the limitations and potential artifacts when using antibodies to study ORP8 in complex with other proteins?

When investigating ORP8 protein complexes, researchers must be vigilant about several methodological limitations that can produce artifacts. Antibody epitope masking is a significant concern, as ORP8's interactions with binding partners may conceal antibody recognition sites, leading to false-negative results. This is particularly relevant when studying ORP8's reported interactions with ORP5 and other lipid transfer proteins at membrane contact sites .

To minimize artifacts when studying ORP8 complexes:

• Employ multiple antibodies targeting different ORP8 epitopes to ensure detection regardless of protein-protein interactions

• Validate co-immunoprecipitation results with reciprocal pulldowns using antibodies against putative binding partners

• Include appropriate detergent controls to distinguish between direct protein-protein interactions and co-localization within membrane microdomains

• Implement proximity-dependent techniques like BioID or APEX2 to validate interactions identified through antibody-based methods

Be aware that standard fixation protocols for immunofluorescence may disrupt transient protein-protein interactions or alter membrane contact site architecture. Address this limitation by combining live-cell imaging of fluorescently tagged proteins with post-fixation immunostaining for endogenous proteins, allowing direct comparison between dynamic behaviors and fixed snapshots.

How can antibody cross-reactivity between ORP8 and ORP5 be addressed in experimental design?

Addressing potential cross-reactivity between ORP5 and ORP8 antibodies is crucial for accurate experimental outcomes due to their structural similarities and overlapping functions . Implement a systematic validation approach including:

• Epitope mapping to identify unique regions for antibody generation

• Western blot validation in cells selectively expressing either ORP5 or ORP8

• Immunostaining in knockdown/knockout models

A definitive validation strategy involves dual knockdown experiments where either ORP5, ORP8, or both are depleted, followed by immunoblotting and immunostaining with the antibodies in question. True ORP8-specific antibodies will show signal reduction only in ORP8 and dual knockdown conditions, while maintaining signal in ORP5 knockdown samples.

For advanced applications requiring absolute specificity, consider the generation of recombinant antibody fragments (Fabs or scFvs) targeting highly divergent regions between these proteins, particularly focusing on the extended β6–β7 loop (His209–Ser236) in the ORP8 PH domain, which represents a distinctive structural feature not found in ORP5 .

What methodologies can resolve discrepancies in ORP8 localization studies using different antibodies?

Discrepancies in ORP8 localization studies often stem from antibody properties, fixation methods, or biological variables. To systematically resolve these inconsistencies:

• Compare antibody epitopes: Map the binding sites of discrepant antibodies, as epitopes in different ORP8 domains may be differentially accessible depending on protein conformation or interaction state

• Standardize fixation protocols: Systematically evaluate how different fixation methods affect epitope accessibility:

  • Paraformaldehyde (cross-linking fixative)

  • Methanol or acetone (precipitating fixatives)

  • Glutaraldehyde (stronger cross-linking for ultrastructural preservation)

• Validate with fluorescent protein fusions: Compare antibody staining patterns with the localization of fluorescently tagged ORP8 variants in live and fixed cells

• Consider physiological variables: Document how ORP8 localization changes with:

  • Cell confluence and cell cycle stage

  • Plasma membrane phosphoinositide composition

  • ER stress or calcium levels

Research has demonstrated that ORP5A forms focused puncta around the cell periphery at mid-cell sections, similar to ER-PM junctions, while ORP8 isoforms show primarily reticular distribution . When discrepancies arise, determine whether they reflect genuine biological variation versus technical artifacts by implementing correlative light and electron microscopy (CLEM) with immunogold labeling to achieve definitive ultrastructural localization.

How can antibodies be used to investigate the dynamic relationship between ORP8 and membrane contact sites?

Investigating the dynamic relationship between ORP8 and membrane contact sites requires techniques that combine temporal resolution with spatial precision. Implement a multi-modal approach using antibodies in both fixed and live-cell contexts:

• Pulse-chase immunofluorescence: Label surface pools of overexpressed extracellular-tagged ORP8 constructs, allow internalization/trafficking, then fix and stain for steady-state markers of contact sites

• Antibody-based FRAP (Fluorescence Recovery After Photobleaching): Use fluorescently-labeled Fab fragments against extracellular epitope-tagged ORP8 to monitor real-time dynamics without crosslinking

• Calcium-dependent contact site modulation: Trigger store-operated calcium entry, fix cells at defined timepoints, then perform quantitative immunofluorescence of ORP8 and contact site markers

For ultrastructural analysis, employ the established GFP-ORP5A and GFP-binding protein Apex2 construct system adapted for ORP8, which generates electron-dense staining at ORP8-enriched ER-PM junction sites. Compare results between ORP8L and ORP8S, as these isoforms demonstrate different distribution patterns, with ORP8L showing stronger reticular ER localization possibly due to the negatively charged residues within its first 42 amino acids .

To monitor phosphoinositide-dependent recruitment dynamics, combine antibody detection of endogenous ORP8 with visualization of PtdIns(4,5)P2 using specific biosensors before and after pharmacological manipulation of phosphoinositide metabolism.

How might antibodies against ORP8 inform our understanding of antibody-mediated feedback in immune responses?

Recent research on antibody-mediated feedback mechanisms in immune responses provides a conceptual framework to explore potential regulatory roles of ORP8 in B cell responses. Antibody-mediated feedback has been shown to steer recall germinal center (GC) B cells away from previously targeted epitopes , a mechanism that might intersect with lipid metabolism pathways involving ORP8.

To investigate this potential connection, design experiments combining ORP8 antibodies with immune cell profiling:

• Compare ORP8 expression and localization patterns in naive versus activated B cells using validated antibodies

• Analyze ORP8 recruitment to immunological synapses during B cell receptor (BCR) stimulation through co-localization studies with BCR components

• Assess whether ORP8 expression/localization changes during germinal center reactions using tissue immunohistochemistry with B cell subset markers

When designing these experiments, consider that ORP8's phosphoinositide transport capabilities might influence BCR signaling, which heavily depends on plasma membrane phosphoinositide composition. Use phospho-specific antibodies against BCR signaling components in ORP8-depleted B cells to determine whether ORP8 modulates these pathways. This approach could reveal previously unrecognized connections between lipid metabolism, membrane organization, and antibody-mediated immune responses.

What methodological approaches can distinguish between ORP8's roles in different membrane contact sites?

ORP8 may function at multiple membrane contact sites beyond ER-PM junctions. To distinguish between these roles, implement a comprehensive subcellular fractionation approach combined with quantitative immunoblotting using ORP8 antibodies. Design a differential centrifugation protocol to isolate distinct membrane contact site fractions, including:

• ER-PM junctions (heavy membrane fraction)

• ER-mitochondria contact sites (mitochondria-associated membranes)

• ER-Golgi contact sites (microsomal fraction)

• ER-endosome/lysosome contacts (endolysosomal fraction)

For each fraction, quantify ORP8 enrichment relative to specific markers of each contact site type. Complement biochemical fractionation with super-resolution microscopy to visualize ORP8 localization relative to contact site markers.

To functionally distinguish between ORP8's roles at different contact sites, design chimeric ORP8 constructs with organelle-specific targeting sequences that restrict localization to specific contact sites. Validate targeting using immunofluorescence with ORP8 antibodies, then assess the impact on phosphoinositide distribution and lipid transfer capabilities at each contact site type. This approach would reveal whether ORP8 performs specialized functions depending on the contact site context or maintains consistent lipid transport activities regardless of localization.